Saturday, 10 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

EUROAPI Stock Went Down By Over 21% At Session Start Today

Loading stream...

(vianews) - shares of euroapi (cac 40: eapi.pa) fell by a staggering 21.81% to €12.51 at 10:54 est on wednesday, after four consecutive sessions in a row of gains. cac 40 is falling 0.15% to €7,328.06, following the last session's downward trend. this seems, at the moment, a somewhat down trend exchanging session today.

about euroapi

euroapi sa develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. it provides contract development manufacturing organization for different classes of tides that uses solid phase chemistry; prostaglandins; steroids & hormones; and opiates and controlled substances. the company was incorporated in 2021 and is headquartered in paris, france.

more news about euroapi (eapi.pa).

Categories

stockMarket

Tags

Stock PricePrice DownEAPI.PAMarket Session NowStock Price DownStock Market NowEUROAPIMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com